Tango Therapeutics Inc Share Price Today: Live Updates & Key Insights

Tango Therapeutics Inc share price today is $19.42, up 0.52%. The stock opened at $19.25 against the previous close of $19.32, with an intraday high of $19.8 and low of $18.82.

Tango Therapeutics Inc Share Price Chart

Tango Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Tango Therapeutics Inc Share Price Performance

$19.42 0.0052(0.52%) TNGX at 23 Mar 2026 03:32 PM Biotechnology
Lowest Today 18.82
Highest Today 19.8
Today’s Open 19.25
Prev. Close 19.32
52 Week High 19.81
52 Week Low 1.03
Day’s Range: Low 18.82 High 19.8
52-Week Range: Low 1.03 High 19.81
1 day return -
1 Week return +8.44
1 month return +52.51
3 month return +124.92
6 month return +160.75
1 year return +1027.9
3 year return +375.49
5 year return +83.36
10 year return -

Tango Therapeutics Inc Institutional Holdings

Farallon Capital Management, L.L.C. 9.15

Boxer Capital Management, LLC 7.62

Adage Capital Partners Gp LLC 7.43

Woodline Partners LP 7.06

TCG Crossover Management, LLC 5.98

Siren, L.L.C. 5.72

TRV GP IV, LLC 5.52

Nextech Invest, Ltd. 5.09

Vanguard Group Inc 4.73

BlackRock Inc 3.96

Balyasny Asset Management LLC 3.70

Bellevue Group AG 2.75

Vanguard Total Stock Mkt Idx Inv 2.74

State Street® SPDR® S&P® Biotech ETF 2.66

Caligan Partners LP 2.61

Nantahala Capital Management, LLC 2.50

T. Rowe Price Investment Management,Inc. 2.47

State Street Corp 2.36

Point72 Asset Management, L.P. 2.05

Deerfield Management Co 2.04

FMR Inc 2.01

Suvretta Capital Management, LLC 1.87

iShares Russell 2000 ETF 1.80

FIAM Small Cap Core CIT Cl B 0.88

Vanguard Institutional Extnd Mkt Idx Tr 0.75

Fidelity Small Cap Index 0.73

iShares Russell 2000 Value ETF 0.64

Franklin Biotechnology Discv A(acc)USD 0.59

Belfius Equities Cure C Cap 0.50

iShares Biotechnology ETF 0.46

State St Russell Sm/Mid Cp® Indx SL Cl I 0.43

Fidelity Extended Market Index 0.36

Vanguard Russell 2000 ETF 0.35

Franklin Biotechnology Discovery A 0.34

Schwab US Small-Cap ETF™ 0.34

Fidelity Select Biotechnology 0.32

Fidelity Series Small Cap Core 0.29

Fidelity Advisor Biotechnology I 0.28

T. Rowe Price US Smlr Coms Eq A 0.26

State St Russell Sm Cap® Indx SL Cl I 0.25

Tango Therapeutics Inc Market Status

Strong Buy: 6

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Tango Therapeutics Inc Fundamentals

Market Cap 2771.02 M

PB Ratio 8.0005

PE Ratio 0.0

Enterprise Value 2460.02 M

Total Assets 398.69 M

Volume 7616804

Tango Therapeutics Inc Company Financials

Annual Revenue FY23:37507000 37.5M, FY22:24860000 24.9M, FY21:37042000 37.0M, FY20:7656000 7.7M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:24860000 24.9M, FY21:37042000 37.0M, FY20:7656000 7.7M, FY19:null 0.0M

Annual Net worth FY23:-100041000 -100.0M, FY22:-108176000 -108.2M, FY21:-58235000 -58.2M, FY20:-51864000 -51.9M, FY19:null 0.0M

Quarterly Revenue Q3/2025:53811000 53.8M, Q2/2025:3181000 3.2M, Q1/2025:5392000 5.4M, Q3/2024:11607000 11.6M, Q2/2024:19875000 19.9M

Quarterly Profit Q3/2025:53256000 53.3M, Q2/2025:2556000 2.6M, Q1/2025:5392000 5.4M, Q3/2024:11607000 11.6M, Q2/2024:19243000 19.2M

Quarterly Net worth Q3/2025:15884000 15.9M, Q2/2025:-38853000 -38.9M, Q1/2025:-39876000 -39.9M, Q3/2024:-29167000 -29.2M, Q2/2024:-25551000 -25.6M

About Tango Therapeutics Inc & investment objective

Company Information Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Organisation Biotechnology

Employees 137

Industry Biotechnology

CEO Dr. Malte Peters M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Tango Therapeutics Inc FAQs

What is the share price of Tango Therapeutics Inc today?

The current share price of Tango Therapeutics Inc is $19.42.

Can I buy Tango Therapeutics Inc shares in India?

Yes, Indian investors can buy Tango Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Tango Therapeutics Inc shares in India?

You can easily invest in Tango Therapeutics Inc shares from India by:

Can I buy fractional shares of Tango Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Tango Therapeutics Inc?

Tango Therapeutics Inc has a market cap of $2771.02 M.

In which sector does Tango Therapeutics Inc belong?

Tango Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Tango Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Tango Therapeutics Inc?

The PE ratio of Tango Therapeutics Inc is N/A and the PB ratio is 8.00.